The size of the Acute Ischemic Stroke Treatment & Diagnosis Market in North America was worth USD 749.73 million in 2019 and estimated to be growing at a CAGR of 6.2%, to reach USD 1012.81 million by 2024.
Acute Ischemic stroke can be defined as loss of function in certain parts of the brain due to a lack of blood supply to the brain.
North America Acute Ischemic Stroke and Diagnosis and treatment are driven by factors such as the rising prevalence of acute ischemia stroke cases, technological advancements in surgical procedures along with rising aging population, increased demand for minimally invasive procedures and growth in healthcare spending. Favorable government policies are also boosting the growth of the market in this region.
Whereas, the excessive usage of medication for the treatment of ischemic stroke and high cost of surgical procedures are restraining the growth of the market.
This research report segmented and sub-segmented into the following categories:
On the basis of surgery type, Carotid Endarterectomy is the largest segment accounting for a share of approximately XX% due to its high success rate, short treatment duration, and easy availability.
On the basis of region, the United States is the largest market for Acute Ischemic Stroke Diagnosis and Treatment devices accounting for a share of approximately XX% in 2019 and is estimated to continue its stronghold of the market owing to favorable government initiatives, technological innovations and increasing demand for ischemic stroke products.
Prominent companies leading the North American Acute Ischemic Stroke Treatment & Diagnosis Market profiled in this report are Abbott Laboratories, Covidien plc, Philips Healthcare, Johnson & Johnson, Penumbra, Inc., GE Healthcare, Siemens Healthcare, Stryker Corporation (Concentric Medical, Inc.) and Hitachi, Ltd.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Type
5.1.1 Computed Tomography
5.1.2 Magnetic Resonance Imaging
5.1.3 Ultrasound
5.1.4 Cerebral angiography
5.1.5 Nuclear Imaging
5.2 Surgery Type
5.2.1 Carotid Endarterectomy
5.2.2 Angioplasty
5.2.3 Endovascular Mechanical Thrombectomy
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Covidien plc
8.3 Johnson & Johnson
8.4 Penumbra, Inc.
8.5 Philips Healthcare
8.6 GE Healthcare
8.7 Hitachi, Ltd.
8.8 Siemens Healthcare
8.9 Stryker Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
